Congress Presentations
Stay informed about the latest scientific and medical research from Axsome.
American Society for Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
Scottsdale, AZ | May 27 - 30, 2025
AXS-05 | Alzheimer’s Disease Agitation
Efficacy and Safety of AXS-05 in Alzheimer's Disease Agitation: Results From ACCORD-2, a Phase 3 Randomized Withdrawal Double-Blind Placebo-Controlled Study
AXS-05 | Alzheimer’s Disease Agitation
Dr. George Grossberg, MD, describes the “Results From ACCORD-2, a Phase 3 Randomized Withdrawal Double-Blind Placebo-Controlled Study” poster
Solriamfetol | Excessive Daytime Sleepiness
Real-world Use of Solriamfetol for Excessive Daytime Sleepiness in Patients Reporting Anxiety or Depression in the Real-World SURWEY Study
AXS-05 | Major Depressive Disorder
Initiating Dextromethorphan 45 mg – Bupropion 105 mg in Patients With Major Depressive Disorder (MDD): Expert Panel Consensus Recommendations
AXS-05 | Major Depressive Disorder
Dr. Anita Clayton presents the “Initiating Dextromethorphan 45 mg – Bupropion 105 mg in Patients With Major Depressive Disorder (MDD): Expert Panel Consensus Recommendations” poster
AXS-05 | Major Depressive Disorder
Supplemental Information for “Initiating Dextromethorphan 45 mg – Bupropion 105 mg in Patients With Major Depressive Disorder (MDD): Expert Panel Consensus Recommendations” – All Recommendations
